Gsa Capital Partners LLP Relmada Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 108,412 shares of RLMD stock, worth $342,581. This represents 0.03% of its overall portfolio holdings.
Number of Shares
108,412
Previous 108,115
0.27%
Holding current value
$342,581
Previous $324,000
8.33%
% of portfolio
0.03%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding RLMD
# of Institutions
82Shares Held
12.4MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$4.11 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.97 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$3.75 Million0.01% of portfolio
-
Parsons Capital Management Inc1MShares$3.17 Million0.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$2.31 Million0.33% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $90.4M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...